This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Psychotherapy for Bipolar II Depression, Pilot Study, Phase II

This study has been completed.
Sponsor:
Collaborator:
National Alliance for Research on Schizophrenia and Depression
Information provided by (Responsible Party):
Holly Swartz, University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT00411463
First received: December 12, 2006
Last updated: April 21, 2017
Last verified: April 2017
December 12, 2006
April 21, 2017
December 2006
September 2010   (Final data collection date for primary outcome measure)
Number of Participants With Greater Than or Equal to 50% Reduction in Depression Scores, With a Mania Score Less Than or Equal to 10 [ Time Frame: Week 12 ]
Overall response rates (defined as greater than or equal to 50% reduction in depression scores without an increase in mania scores) were 29% (n=4) in the IPSRT group and 27% (n=3) in the quetiapine group. HRSD-25 scores are based on first 17 responses. Eight items are scored on a 5-pt scale, from 0 (not present) to 4 (severe.) Other nine items on the assessment are scored from 0-2. The higher the score on the HRSD-25, the worse the outcome is considered to be. A score of 0-7 is considered to be normal; 8-13 indicates mild depression, 14-18 indicates moderate depression, 19-22 indicates severe depression, and any score greater than or equal to 23 indicates very severe depression. The YMRS is an 11 point assessment. There are 4 items assessed on a scale ranging from 0 to 8 and the other 7 items are graded on a 0 to 4 scale. As with the HRSD, the higher the score on the YMRS indicates the presence of more or more severe manic symptoms and is associated with a worse outcome.
  • Change on measures of depression and anxiety (HRSD),
  • quality of life (QOL).
Complete list of historical versions of study NCT00411463 on ClinicalTrials.gov Archive Site
  • Quality of Life (QOL) Collected Using the Q-LES-Q (Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form) [ Time Frame: Baseline and Week 12 ]
    The total score is derived by summing item scores 1 to 14. Higher scores are indicative of greater enjoyment or satisfaction in each domain. The Q-LES-Q-SF % maximum total score is calculated as 100% × (Q-LES-Q-SF total score - 14) / 56, and can range from 0% to 100%.
  • Descriptive Measures of the Feasibility of IPSRT-BPII [ Time Frame: Week 12 ]
    Feasibility was assessed by ability to enroll, randomize, and retain participants in this trial. Completion of the study was used as evidence of feasibility.
  • Number of Participants With a Response [ Time Frame: Week 12 ]
    Number of participants with response defined as an average of 50% (or greater) reduction in the subject's baseline HRSD-25 score over three consecutive weeks and a current YMRS score ≤ 10
Descriptive measures of the feasiblity of IPSRT-BPII
Not Provided
Not Provided
 
Psychotherapy for Bipolar II Depression, Pilot Study, Phase II
Psychotherapy for Bipolar II Depression, Pilot Study, Phase II
Purpose of this study is to examine the effectiveness of an experimental psychotherapy (talk therapy) for the treatment of bipolar II depression. The name of this psychotherapy is Interpersonal and Social Rhythm Therapy for Bipolar II Depression (IPSRT-BPII). Subjects will be randomly assigned to receive either IPSRT-BPII or the medication Seroquel (quetiapine) to manage their symptoms of bipolar II depression. Subjects will receive the assigned therapy for up to 20 weeks.
The proposed pilot study is an experimental design intended to investigate the preliminary efficacy of Interpersonal Social Rhythm Therapy for Bipolar II Depression (IPSRT-BPII). A total of 56 eligible subjects with a diagnosis of bipolar II disorder will be randomly assigned to one of two treatment groups : Seroquel (n=28) or IPSRT-BPII (n=28). Following baseline assessment, all participants will undergo up to 20 weeks of their assigned treatment. Patients assigned to IPSRT-BPII who fail to respond (at least 50% reduction in HRSD-25 scores and YMRS ≤ 10) by week 12 will have Seroquel added to IPSRT-BPII. Subjects who achieve remission (defined as 3 consecutive weeks where both HRSD-25 and YMRS scores average ≤ 7) and have participated in the trial for a minimum of 12 weeks will be moved into a continuation phase where they will receive maintenance treatment (bi-monthly therapy sessions and/or pharmacotherapy) until week 20. Patients who do not achieve remission by Week 20 will be discontinued from treatment and referred for follow-up care. All subjects (remitters and non-remitters) will be assessed at 20 weeks.
Interventional
Phase 2
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Bipolar II Disorder
  • Behavioral: Interpersonal and Social Rhythm Therapy (IPSRT-BPII)

    IPSRT is comprised of three components: psychoeducation, social rhythm therapy, and standard IPT as developed for unipolar depression.

    Psychoeducation focuses on a) the illness and its consequences, b) treatment options and associated side effects, and c) prodromal symptoms/detection of early warning symptoms.

    Other Name: IPSRT
  • Drug: Seroquel

    Subjects will be started at 100 mg/day titrated to a maximum of 800 mg /day

    Day 1-BID doses totaling 100 mg/day, increased to 400 mg/day on Day 4 in increments of up to 100 mg/day in BID divided doses, by Day 6 begin titration up to a maximum dose of 800 mg/day in increments no greater than 200 mg/day.

    This titration schedule may be adjusted based on the subject's response and ability to tolerate Seroquel.

    Subjects who are unable to tolerate the study medications, or for whom the study medications are an inappropriate clinical choice, will be treated openly by a clinic physician according to the standard of care guidelines designated by the American Psychiatric Association (2002) for the treatment of bipolar disorder.

    Other Name: Quetiapine
  • Experimental: Psychotherapy
    Subjects randomized to the Psychotherapy arm will receive Interpersonal and Social Rhythm Therapy (IPSRT-BPII)
    Intervention: Behavioral: Interpersonal and Social Rhythm Therapy (IPSRT-BPII)
  • Experimental: Medication
    Subjects randomized to the medication arm will receive the FDA approved medication Seroquel (quetiapine)
    Intervention: Drug: Seroquel
Swartz HA, Frank E, Cheng Y. A randomized pilot study of psychotherapy and quetiapine for the acute treatment of bipolar II depression. Bipolar Disord. 2012 Mar;14(2):211-6. doi: 10.1111/j.1399-5618.2012.00988.x.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
25
September 2010
September 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Meets DSM-IV Criteria for Bipolar Disorder, Type II, currently depressed;
  2. HRSD-25 ≥15
  3. Age 18-65 years;
  4. Able to give informed consent;
  5. Women of child bearing potential will be included if they agree to use adequate contraception for the duration of the study.

Exclusion Criteria:

  1. Not competent to give informed consent in the opinion of the investigator (e.g., psychotic at time of evaluation);
  2. Unwilling or unable to comply with study requirements;
  3. Meets DSM-IV criteria for borderline personality disorder or antisocial personality disorder;
  4. Active substance abuse within the past 6 months(episodic abuse related to mood episodes will not exclude a subject);
  5. Currently a high suicide risk, as assessed by an active plan and intent to behave in a way that risks ending ones life;
  6. Non-English speaking;
  7. Significant, unstable, medical illness that might confound symptom scores or preclude treatment with pharmacotherapy
  8. Currently applying for disability because of psychiatric illness (we have found that these individuals have a vested interested in appearing to remain ill which potentially confounds outcome scores).
  9. Women who are pregnant, lactating or plan to become pregnant during their study participation.
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00411463
0608080
No
Not Provided
No
Not Provided
Holly Swartz, University of Pittsburgh
University of Pittsburgh
National Alliance for Research on Schizophrenia and Depression
Principal Investigator: Holly Swartz, M.D. University of Pittsburgh
University of Pittsburgh
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP